Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter
Primary Purpose
Fecal Incontinence, Anal Incontinence
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Injection of autologous muscle fibers into the anal sphincter.
Pelvic floor muscle training
Dietary intervention
Analgesia
Sponsored by
About this trial
This is an interventional treatment trial for Fecal Incontinence focused on measuring regenerative medicine, fecal incontinence, muscle fiber injection
Eligibility Criteria
Inclusion Criteria:
- fecal incontinence
- Wexner score >= 9 or affected quality of life.
- Understanding and speaking danish
- Informed consent
Exclusion Criteria:
- Ongoing pregnancy
- Delivery in the last 12 months
- colostomy
- chronic inflammatory bowel disease (mb. crohn, colitis ulcerosa)
- improvement after pelvic floor muscle training in an extent that makes autologous muscle fiber injection unnecessary.
Sites / Locations
- Department of Obstetrics and Gynaecology, Herlev University HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Injection of autologous muscle fibers in the anal sphincter
Arm Description
All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
Outcomes
Primary Outcome Measures
Efficacy of the treatment using fecal incontinence score: Wexner score.
Secondary Outcome Measures
Safety
Number of adverse events, pain etc.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01949922
Brief Title
Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter
Official Title
Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter - a Pilot Study.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2013 (undefined)
Primary Completion Date
January 2017 (Anticipated)
Study Completion Date
January 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Aim:
To investigate efficacy and safety in a new treatment with injection of autologous muscle fibers into the anal sphincter in patients with fecal incontinence.
Method:
Patients with fecal incontinence after obstetric anal sphincter rupture will be included. After inclusion, they will be offered 3 months of pelvic floor muscle training. If the patients after completion of pelvic floor muscle training still suffer from fecal incontinence, the patients will be offered treatment with autologous muscle fiber injection into the anal sphincter. The patients will be followed one year after the injection. The autologous muscle fibers are harvested at the patients leg muscle, cut into small pieces and injected into the anal sphincter. A small part of the fibers are used for analysing number of muscle stem cells and thereby the regenerative potential of the sample.
The study is a pilot study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence, Anal Incontinence
Keywords
regenerative medicine, fecal incontinence, muscle fiber injection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Injection of autologous muscle fibers in the anal sphincter
Arm Type
Experimental
Arm Description
All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
Intervention Type
Procedure
Intervention Name(s)
Injection of autologous muscle fibers into the anal sphincter.
Intervention Type
Procedure
Intervention Name(s)
Pelvic floor muscle training
Intervention Description
Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
Intervention Type
Behavioral
Intervention Name(s)
Dietary intervention
Intervention Description
Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
Intervention Type
Drug
Intervention Name(s)
Analgesia
Intervention Description
Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
Primary Outcome Measure Information:
Title
Efficacy of the treatment using fecal incontinence score: Wexner score.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Safety
Description
Number of adverse events, pain etc.
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Improvement of life quality
Time Frame
1 year
Title
Improvement of anal sphincter functioning assessed by anal reflectometry
Time Frame
1 year.
Title
Improvement of fecal incontinence after pelvic floor muscle training.
Time Frame
3 months
Title
Improvement of the anal sphincter by 3D ultrasound.
Time Frame
1 year
Title
Correlation between the tissue samples regenerative potential and effect of treatment.
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
fecal incontinence
Wexner score >= 9 or affected quality of life.
Understanding and speaking danish
Informed consent
Exclusion Criteria:
Ongoing pregnancy
Delivery in the last 12 months
colostomy
chronic inflammatory bowel disease (mb. crohn, colitis ulcerosa)
improvement after pelvic floor muscle training in an extent that makes autologous muscle fiber injection unnecessary.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanna Jangö, MD, ph.d.-student
Phone
+4538689649
Email
hanna.jango@regionh.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Søren Gräs, MD, senior consultant
Phone
+4538682361
Email
soeren.gras@regionh.dk
Facility Information:
Facility Name
Department of Obstetrics and Gynaecology, Herlev University Hospital
City
Copenhagen
State/Province
Herlev
ZIP/Postal Code
DK-2730
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanna Jangö, MD, PhD-student
Phone
+4538689649
Email
hanna.jango@regionh.dk
First Name & Middle Initial & Last Name & Degree
Søren Gräs, MD, senior consultant
Phone
+4538682361
Email
soeren.gras@regionh.dk
First Name & Middle Initial & Last Name & Degree
Hanna Jangö, MD
First Name & Middle Initial & Last Name & Degree
Søren Gräs, MD
First Name & Middle Initial & Last Name & Degree
Gunnar Lose, Prof, DMSc
First Name & Middle Initial & Last Name & Degree
Niels Klarskov, DMSc, MD
12. IPD Sharing Statement
Learn more about this trial
Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter
We'll reach out to this number within 24 hrs